OBJECTIVES: Management of liver metastasis (LM) from a non-colorectal, non-neuroendocrine primary carcinoma remains controversial. Few data exist on the management of hepatic metastasis from primary renal cell carcinoma (RCC). This study sought to determine the safety and efficacy of surgery for RCC LM. METHODS: A total of 43 patients who underwent surgery for RCC hepatic metastasis between 1994 and 2011 were identified in a multi-institution hepatobiliary database. Clinicopathologic, operative and outcome data were collected and analysed. RESULTS: Mean patient age was 62.4 years and most patients (67.4%) were male. The mean tumour size of the primary RCC was 6.9 cm and most tumours (72.1%) were designated as clear cell carcinoma. Nine patients (20.9%) presented with synchronous LM. Among the patients with metachronous disease, the median time from diagnosis of the primary RCC to treatment of LM was 17.2 months (range: 2.1-189.3 months). The mean size of the RCC LM was 4.0 cm and most patients (55.8%) had a solitary metastasis. Most patients (86.0%) underwent a minor resection (up to three segments). Final pathology showed margin status to be negative (R0) in 95.3% of patients. Postoperative morbidity was 23.3% and there was one perioperative death. A total of 69.8% of patients received perioperative chemotherapy. Overall 3-year survival was 62.1%. Three-year recurrence-free survival was 27.3% and the median length of recurrence-free survival was 15.5 months. CONCLUSIONS: Resection of RCC hepatic metastasis is safe and is associated with low morbidity and near-zero mortality. Although recurrence occurs in up to 50% of patients, resection can be associated with long-term survival in a well-selected subset of patients.
OBJECTIVES: Management of liver metastasis (LM) from a non-colorectal, non-neuroendocrine primary carcinoma remains controversial. Few data exist on the management of hepatic metastasis from primary renal cell carcinoma (RCC). This study sought to determine the safety and efficacy of surgery for RCC LM. METHODS: A total of 43 patients who underwent surgery for RCC hepatic metastasis between 1994 and 2011 were identified in a multi-institution hepatobiliary database. Clinicopathologic, operative and outcome data were collected and analysed. RESULTS: Mean patient age was 62.4 years and most patients (67.4%) were male. The mean tumour size of the primary RCC was 6.9 cm and most tumours (72.1%) were designated as clear cell carcinoma. Nine patients (20.9%) presented with synchronous LM. Among the patients with metachronous disease, the median time from diagnosis of the primary RCC to treatment of LM was 17.2 months (range: 2.1-189.3 months). The mean size of the RCC LM was 4.0 cm and most patients (55.8%) had a solitary metastasis. Most patients (86.0%) underwent a minor resection (up to three segments). Final pathology showed margin status to be negative (R0) in 95.3% of patients. Postoperative morbidity was 23.3% and there was one perioperative death. A total of 69.8% of patients received perioperative chemotherapy. Overall 3-year survival was 62.1%. Three-year recurrence-free survival was 27.3% and the median length of recurrence-free survival was 15.5 months. CONCLUSIONS: Resection of RCC hepatic metastasis is safe and is associated with low morbidity and near-zero mortality. Although recurrence occurs in up to 50% of patients, resection can be associated with long-term survival in a well-selected subset of patients.
Authors: Bolanle Asiyanbola; Ana Gleisner; Joseph M Herman; Michael A Choti; Christopher L Wolfgang; Michael Swartz; Barish H Edil; Richard D Schulick; John L Cameron; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2008-12-17 Impact factor: 3.452
Authors: Robert J Motzer; Neeraj Agarwal; Clair Beard; Graeme B Bolger; Barry Boston; Michael A Carducci; Toni K Choueiri; Robert A Figlin; Mayer Fishman; Steven L Hancock; Gary R Hudes; Eric Jonasch; Anne Kessinger; Timothy M Kuzel; Paul H Lange; Ellis G Levine; Kim A Margolin; M Dror Michaelson; Thomas Olencki; Roberto Pili; Bruce G Redman; Cary N Robertson; Lawrence H Schwartz; Joel Sheinfeld; Jue Wang Journal: J Natl Compr Canc Netw Date: 2009-06 Impact factor: 11.908
Authors: Skye C Mayo; Marta M Gilson; Joseph M Herman; John L Cameron; Hari Nathan; Barish H Edil; Michael A Choti; Richard D Schulick; Christopher L Wolfgang; Timothy M Pawlik Journal: J Am Coll Surg Date: 2011-11-04 Impact factor: 6.113
Authors: Skye C Mayo; Jennifer E Heckman; Andrew D Shore; Hari Nathan; Alexander A Parikh; John F P Bridges; Robert A Anders; Daniel A Anaya; Natasha S Becker; Timothy M Pawlik Journal: Surgery Date: 2011-08 Impact factor: 3.982
Authors: Stephen H Culp; Nizar M Tannir; E Jason Abel; Vitaly Margulis; Pheroze Tamboli; Surena F Matin; Christopher G Wood Journal: Cancer Date: 2010-07-15 Impact factor: 6.860
Authors: Carlo Pulitanò; Martin Bodingbauer; Luca Aldrighetti; Mechteld C de Jong; Federico Castillo; Richard D Schulick; Rowan W Parks; Michael A Choti; Stephen J Wigmore; Thomas Gruenberger; Timothy M Pawlik Journal: Ann Surg Oncol Date: 2010-12-07 Impact factor: 5.344
Authors: Joachim Pfannschmidt; Hans Hoffmann; Thomas Muley; Sabine Krysa; Christine Trainer; Hendrik Dienemann Journal: Ann Thorac Surg Date: 2002-11 Impact factor: 4.330
Authors: Sarah B Fisher; Peter J Kneuertz; Rebecca M Dodson; Sameer H Patel; Shishir K Maithel; Juan M Sarmiento; Maria C Russell; Kenneth Cardona; Michael A Choti; Charles A Staley; Timothy M Pawlik; David A Kooby Journal: HPB (Oxford) Date: 2013-07-22 Impact factor: 3.647
Authors: Bela Kis; Jehan Shah; Junsung Choi; Ghassan El-Haddad; Jennifer Sweeney; Benjamin Biebel; Eric Mellon; Jessica M Frakes; Sarah E Hoffe; Mayer N Fishman; Ravi Shridhar Journal: J Vasc Interv Radiol Date: 2016-12-07 Impact factor: 3.464
Authors: Hans Michael Hau; Florian Thalmann; Christoph Lübbert; Mehmet Haluk Morgul; Moritz Schmelzle; Georgi Atanasov; Christian Benzing; Undine Lange; Rudolf Ascherl; Roman Ganzer; Dirk Uhlmann; Hans-Michael Tautenhahn; Georg Wiltberger; Michael Bartels Journal: BMC Surg Date: 2016-07-22 Impact factor: 2.102